Ir a inicio
820К+ pacientes han recibido asistencia desde 2014
50 países
1,500 clínicas
6K+ reseñas
3K+ médicos calificados

¿Cuál es el precio del diagnóstico y los tratamientos de Enfermedad de alzheimer en China? Descubra ahora

El precio se proporciona bajo petición
ChinaEspañaTurquía
Tratamiento con células madre para Alzheimerde $22,000de $20,000de $15,000
Datos verificados por Bookimed a partir de May 2026, basados en solicitudes de pacientes y cotizaciones oficiales de 137 clínicas en todo el mundo. Los costos medianos se basan en facturas reales (2025–2026) y se actualizan mensualmente. Los precios reales pueden variar.

Sus beneficios y garantías con Bookimed

Precios directos

Bookimed no añade cargos extra a los precios de los tratamientos de Enfermedad de alzheimer. Las tarifas proceden de las listas de precios oficiales de las clínicas. Pagará directamente en la clínica por su tratamiento a su llegada al país.

Sólo clínicas y médicos verificados

Bookimed está comprometido con su seguridad. Solo trabajamos con las clínicas que mantienen altos estándares internacionales en el tratamiento de Enfermedad de alzheimer y cuentan con las licencias necesarias para atender a pacientes internacionales en todo el mundo.

Asistencia 24/7 gratuita

Bookimed ofrece asistencia experta gratuita. Un coordinador médico personal le apoya antes, durante y después de su tratamiento, resolviendo cualquier problema. Nunca estará solo en su viaje médico de tratamiento de Enfermedad de alzheimer.

¿Por qué nosotros?

Su coordinador médico personal de Bookimed

  • Le apoya en cada etapa
  • Ayuda a elegir la clínica y el médico adecuados
  • Asegura un acceso rápido y conveniente a la información

Descubra las mejores clínicas de tratamiento de Enfermedad de alzheimer en China: 1 opciones verificadas y Precios

El ranking de clínicas de Bookimed se basa en algoritmos de data science, ofreciendo una comparación confiable, transparente y objetiva. Tiene en cuenta la demanda de pacientes, las puntuaciones de reseñas (positivas y negativas), la frecuencia de actualización de opciones de tratamiento y precios, la rapidez de respuesta y las certificaciones de las clínicas.

Obtenga una evaluación médica para Enfermedad de alzheimer en China: consulte con doctores experimentados ahora

Ver todos los médicos
verificado

Zheng Wei Hong

45 años de experiencia

El profesor ZHENG Wei Hong es director del Departamento de Neurología y líder de la especialidad. Anteriormente fue director de Neurología del Hospital Zhongshan afiliado a la Universidad de Xiamen. Es profesor en la Universidad de Xiamen y tutor de maestría.

Su enfoque clínico incluye la investigación etiológica, la prevención y el tratamiento del infarto cerebral y la hemorragia cerebral. Asimismo, diagnostica y trata enfermedades neurológicas complejas, como la epilepsia, los trastornos neuroinmunológicos y neuromusculares (miastenia gravis, esclerosis múltiple) y la enfermedad de Parkinson.

Cargos: Miembro de los comités de Neuroinmunología (Rama de Neurología de la Asociación Médica China), Inmunología (Asociación China de Ictus), Neurorestauración (Asociación China de Médicos) y Deterioro Cognitivo (Sociedad China de Geriatría). Miembro del Comité Permanente del Comité de Expertos de los hospitales base del proyecto de cribado y prevención del ictus (Ministerio de Salud). Miembro del Grupo de Expertos en Neurología del Centro Provincial de Control de Calidad Médica de Fujian para ictus y epilepsia. Director permanente de la Asociación contra la Epilepsia de Fujian. Subjefe del Grupo de Epilepsia y Electroencefalografía (Rama de Neurología de la Asociación Médica de Fujian). Vicepresidente del Primer Comité de la Rama de Médicos Neurólogos (Asociación de Médicos de Fujian). Miembro del Comité Permanente (5.º–7.º mandatos) de la Rama de Neurología (Asociación Médica de Fujian). Vicepresidente del Comité Profesional de Neurología (Asociación Médica de Xiamen).

verificado

Shao Ming

32 años de experiencia

Neurólogo líder y Doctor en Ciencias Médicas con formación posdoctoral en la Universidad de Harvard y otras instituciones de prestigio.

  • 31 años de experiencia en neurología
  • Autor de más de 50 artículos científicos, incluyendo 30 en revistas internacionales
  • Introdujo el propofol para el test de Wada en China
  • Presidente de múltiples comités neurológicos en China
  • Especializado en epilepsia, trastornos del movimiento y monitorización neurofisiológica

Artículos relacionados

Compartir contenido

Historias en video de pacientes de Bookimed

Dayana
Combiné mis vacaciones en Antalya con un chequeo médico.
Procedimiento: Chequeo femenino
Igor
¡Fue genial! Traslados, alojamiento, tratamiento, todo incluido.
Procedimiento: Implante dental
Clínica: WestDent Clinic
Marina
Bookimed se encargó de todo. No tuve que preocuparme por nada.
Procedimiento: Chequeo femenino
Actualizado: 10/23/2024
Escrito por
Olena Sikoza
Olena Sikoza
Сopywriter en español
Copywriter médica certificada responsable del contenido en español de Bookimed. Más de 7 años de experiencia en redacción sobre salud y turismo médico, con formación académica en edición científica y desarrollo de contenidos.
Fahad Mawlood
Editor médico y Científico de datos
Médico general. Ganador de 4 premios científicos. Sirvió en Asia Occidental. Es el ex jefe del equipo médico que soporta a pacientes de habla árabe. Ahora es responsable del procesamiento de datos y la precisión del contenido médico.
Fahad Mawlood Linkedin
Esta página puede incluir información relacionada con diversas afecciones médicas, tratamientos y servicios de salud disponibles en diferentes países. Tenga en cuenta que el contenido se proporciona sólo con fines informativos y no debe interpretarse como asesoramiento médico o orientación. Por favor consulte con su médico o con un profesional médico calificado antes de comenzar o cambiar el tratamiento médico.

Preguntas frecuentes sobre el tratamiento de Enfermedad de alzheimer en China

Estas preguntas frecuentes provienen de pacientes reales que buscan atención médica a través de Bookimed. Las respuestas son proporcionadas por coordinadores médicos experimentados y representantes autorizados de las clínicas.

Is Alzheimer’s disease treatment in China safe for international patients?

Alzheimer’s disease treatment in China is safe when patients choose accredited tertiary facilities like Dr. Eber Brain Hospital. These centers employ specialists with training from Harvard and UT. Standard protocols include globally approved monoclonal antibodies. Patients must prioritize JCI or ISO-certified hospitals to ensure Western-level safety standards.

  • Specialized expertise: Neurologists like Dr. Shao Ming hold postdoctoral fellowships from Harvard and Dartmouth.
  • Approved medications: Centers utilize globally recognized drugs like Leqembi and Kisunla for early symptoms.
  • Facility standards: Leading hospitals maintain 300+ beds and over 60 specialized neurological departments.
  • Regulatory oversight: The National Health Commission mandates written informed consent and strict licensing protocols.

Bookimed Expert Insight: While many seek low-cost options, safety in China is tied to academic credentials rather than price. Our data shows that top-performing neurologists, such as Dr. Zheng Wei Hong, often hold dual roles as university professors and committee members for the Ministry of Health. Selecting a doctor with these institutional ties ensures the treatment follows national safety guidelines and uses verified pharmaceutical chains.

Patient Consensus: Patients emphasize the need for independent medical translators to bridge language gaps in public hospitals. They also recommend verifying clinical trial data before traveling for any experimental stem cell procedures.

What treatment modalities are currently offered for Alzheimer’s disease in China?

Alzheimer treatment in China includes anti-amyloid monoclonal antibodies like Lecanemab and unique domestic medications such as Sodium Oligomannate. Specialized centers provide stem cell therapy and neurostimulation. These modalities target amyloid plaques, gut microbiome regulation, and cognitive rehabilitation within modern tertiary-level facilities.

  • Pharmacological therapies: Approved drugs include Lecanemab, Donanemab, and the seaweed-derived oral medication Sodium Oligomannate.
  • Neuromodulation: Centers use non-invasive transcranial magnetic stimulation (rTMS) to improve memory and language.
  • Cellular therapy: Clinics in major cities like Tianjin offer stem cell therapy for neurorestoration.
  • Integrative medicine: Protocols combine Western neurology with acupuncture and herbal compounds like Huperzine A.

Bookimed Expert Insight: Leading neurologists like Dr. Shao Ming at Dr. Eber Brain Hospital often bring prestigious international training from Harvard and the University of Texas to Chinese treatment protocols. This background allows them to combine domestic drug innovations with Western diagnostic precision in complex neurology cases. Patients should look for doctors with such global credentials when seeking advanced neurophysiological monitoring.

Patient Consensus: Patients note that standard drugs are easily accessible in major cities, but emphasize that integrated TCM approaches like acupuncture often work best when combined with Western medicine. Families suggest focusing on Tier-1 city hospitals to ensure access to authentic medications and avoid counterfeit risks.

How is eligibility for Alzheimer’s therapy determined, and are there age or stage limitations?

Eligibility for Alzheimer’s therapy depends on a clinical diagnosis of mild cognitive impairment or early-stage dementia. Patients must prove amyloid-positive status via PET scans or cerebrospinal fluid analysis. While guidelines focus on adults aged 50 to 90, cognitive stage and overall health outweigh biological age.

  • Clinical stage: Eligibility requires early symptomatic stages including mild cognitive impairment or mild dementia.
  • Biological markers: Positive amyloid-beta plaques must be confirmed through brain imaging or fluid analysis.
  • Functional status: Candidates must maintain independence in basic daily activities like dressing or bathing.
  • Safety exclusions: Severe vascular disease or concurrent use of blood thinners often prevents eligibility.
  • Age range: Most therapies target ages 50 to 90 with case-by-case reviews for others.

Bookimed Expert Insight: Focus on tertiary centers in tier-1 cities like Beijing or Tianjin for complex diagnostics. Dr. Eber Brain Hospital in Tianjin features 63 departments specializing in neurological restoration. Specialized neurologists like Dr. Shao Ming at this facility have extensive international research experience in memory impairment. This high level of specialization is critical because general hospitals may delay the biomarkers testing required for early treatment.

Patient Consensus: Patients emphasize that the diagnosis process often takes over a year. Many regret waiting and advise seeking a neurologist immediately rather than relying on primary care visits. They note that being proactive with amyloid testing is the only way to catch the narrow window for newer therapies.

What side-effects or risks should patients anticipate with Alzheimer’s medications in China?

Patients should anticipate gastrointestinal distress or neurological changes from Alzheimer’s medications in China. Newer amyloid-targeting antibodies like lecanemab carry a 9.4% risk of microhemorrhages. Symptom-relieving drugs often cause nausea or insomnia. Specialized monitoring helps manage these risks safely within Chinese clinical settings.

  • Amyloid-related abnormalities: Lecanemab carries risks of brain swelling (3.1%) or microhemorrhages (9.4%).
  • Gastrointestinal distress: Donepezil and Galantamine frequently cause nausea, vomiting, and persistent diarrhea.
  • Neurological risks: Patients may experience vivid dreams, night terrors, agitation, or sudden dizziness.
  • Cardiac concerns: Drugs like rivastigmine may cause bradycardia or slow heart rate.

Bookimed Expert Insight: Coordination of care is vital when combining Western drugs with Traditional Chinese Medicine (TCM). Our data shows that top neurologists like Dr. Zheng Wei Hong at Xiamen Humanity Hospital specialize in both cognitive impairment and neuroimmunology. This dual expertise is crucial because internal research suggests herbal combinations can sometimes lead to unpredictable bleeding risks or increased sedation when used alongside standard prescriptions. We recommend patients verify all medications through hospital pharmacies to ensure authenticity and safety.

Patient Consensus: Many families report being surprised by heart rate drops or fainting. They emphasize the need to start with low doses and verify all medications at hospital pharmacies to avoid quality issues.

How long will I need to stay in China for evaluation and initial Alzheimer’s therapy?

International patients typically stay in China for 1 to 4 weeks for initial Alzheimer’s evaluation and therapy. This period covers specialized biomarker testing and neuroimaging. It also includes the start of protocols like stem cell therapy or specific localized drug monitoring. Professional medical support is essential for communication.

  • Diagnostic phase: Initial scans and cognitive testing usually take 3 to 7 days.
  • Treatment duration: Initial therapy cycles or infusions often require 1 to 2 additional weeks.
  • Safety monitoring: Facilities like Dr. Eber Brain Hospital provide inpatient observation to manage responses.
  • Visa requirements: Stays over 30 days for extended observation require an S2 medical visa.

Bookimed Expert Insight: While small clinics may offer 10-day diagnostic windows, quaternary centers like Dr. Eber Brain Hospital operate with over 400 doctors across 63 departments. This massive scale often means internal coordination takes longer but provides more thorough results. A 4-week stay is actually safer for patients traveling long distances to manage any initial treatment side effects.

Patient Consensus: Patients emphasize budgeting 6 weeks to avoid rushed protocols and account for potential language barriers. Many suggest securing travel insurance that covers experimental treatments to handle unexpected extensions or observation needs.

Will I be able to continue Alzheimer’s medication prescribed in China once I return home?

Continuing Alzheimer medication from China depends on local drug approval and customs rules. Globally approved drugs like Lecanemab are often transferable. However, China-specific treatments like Oligomannate or stem cell therapy protocols require a local neurologist assessment for long-term care in your home country.

  • Import limits: Most countries allow a 90-day supply for personal use at customs.
  • Mandatory documentation: Carry an English-translated prescription and a formal medical summary explaining diagnosis.
  • Local prescription: Home pharmacies cannot refill foreign prescriptions directly without local physician approval.
  • Generic availability: Identify medications by generic names to help local doctors find equivalent versions.

Bookimed Expert Insight: While China leads in neurorestorative research at facilities like Dr. Eber Brain Hospital, these advanced protocols often differ from Western standards. Our data shows that doctors like Dr. Zheng Wei Hong emphasize a transition period where home doctors perform fresh bloodwork before re-prescribing. Do not assume your home neurologist will continue a Chinese protocol without first reviewing these specific clinical records.

Patient Consensus: Patients note that keeping medications in original containers with English labels is vital for passing customs. Many recommend coordinating with a local neurologist before leaving China to avoid gaps in daily treatment.

Do I need special preparation or follow-up tests after returning home?

Clinical follow-up for Alzheimer's treatment in China typically involves virtual monitoring rather than mandatory in-person tests. Patients should prioritize rest and hydration before traveling home. Standard medical evaluations by a local neurologist are recommended within 1 to 3 months to track cognitive progress objectively.

  • Travel preparation: Focus on rest and hydration before long-haul flights after infusions.
  • Virtual monitoring: Establish communication via messaging apps for monthly symptom tracking with staff.
  • Cognitive assessments: Schedule independent exams like MoCA or MMSE with a local specialist.
  • Medication review: Discuss any clinic-recommended supplements with your primary physician upon return.

Bookimed Expert Insight: Chinese neurology centers like Dr. Eber Brain Hospital emphasize multidisciplinary approaches including rehabilitation. Because international data coordination is limited, patients should record their own baseline metrics before treatment. This creates a clear benchmark for local doctors to measure post-treatment improvements in motor function or memory.

Patient Consensus: Patients note that formal follow-up is often just a brief video call or phone quiz. Many recommend using independent cognitive apps and private scans at home to verify any neural changes described by the clinic.

Pedir una consulta gratis

Seleccione la mejor manera de contactarle